Clinical trials: Schizophrenia Spectrum Disorders
Schizophrenia
Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
This study will determine whether adding the drug risperidone (Risperdal®) is more effective than placebo in treating schizophrenic patients who are taking the drug clozapine.
- Trial name
- NCT00056498
- Testing
- Risperdal
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder
Kuvan in People With Schizophrenia and Schizoaffective Disorder
Rater blinded trial of six weeks of Kuvan vs. multivitamin in 60 outpatients with schizophrenia or schizoaffective disorder. The aims are to evaluate an anticipated clinical response to Kuvan treatment including negative symptom…
- Trial name
- NCT01706965
- Testing
- Kuvan, Multivitamin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia
A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
This study will evaluate the safety and durability of effect of ALKS 9072 (also known as ALKS 9070) during long-term treatment of subjects with stable schizophrenia.
- Trial name
- NCT01626456
- Testing
- ALKS 9072, Low, ALKS 9072, High
- Where
- 82 sites in United States, Bulgaria and 6 more
- Volunteers
- 478 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
A Study of Paliperidone Palmitate 6-Month Formulation
The purpose of this study is to demonstrate that injection cycles consisting of a single administration of paliperidone palmitate 6-month (PP6M) are not less effective than 2 sequentially administered injections of paliperidone…
- Trial name
- NCT03345342
- Testing
- PP6M, PP3M 350 mg eq., PP3M 525 mg eq.
- Where
- 138 sites in United States, Argentina and 19 more
- Volunteers
- 841 people
- Sponsor
- Janssen Research & Development, LLC
Suicide, Psychosis
Cognitive Behavioral Suicide Prevention for Psychosis: Aim 1
The investigators are modifying and testing the preliminary effectiveness and implementation of a Cognitive Behavioral Suicide Prevention for psychosis (CBSPp) intervention.
- Trial name
- NCT04689867
- Testing
- Cognitive Behavioral Suicide Prevention for psychosis CBSPp)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan
Schizophrenia
Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics.
- Trial name
- NCT00149734
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Schizophrenia
Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus
This study is a six-week, open label trial of the novel antipsychotic agent, ziprasidone, added to a stable dose of clozapine or olanzapine in 40 diabetes mellitus patients, patients with an impaired fasting glucose or insulin…
- Trial name
- NCT00351000
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association
Schizophrenia
D-serine and Cognitive Remediation in Schizophrenia
The investigators will test the effects of 3 days of D-serine (DSR) on auditory plasticity in a sensory based remediation (SBR) paradigm
- Trial name
- NCT02156908
- Testing
- D-serine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia, Bipolar Disorder
Aripiprazole Open-Label, Safety and Tolerability Study
The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.
- Trial name
- APEX 241 (NCT00102518)
- Testing
- Aripiprazole
- Where
- 50 sites in United States
- Volunteers
- 325 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Safety and Effectiveness of D-serine in Schizophrenia
This study will determine whether increasing D-serine within the body will improve negative symptoms and cognitive impairments in people with schizophrenia.
- Trial name
- NCT00322023
- Testing
- D-serine
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Cannabis Dependence, Marijuana Dependence
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
Cannabis use disorders are an important public health problem in the United States, but no effective pharmacotherapies are available to treat these disorders.
- Trial name
- DCCS (NCT01598896)
- Testing
- Dronabinol, Clonidine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mclean Hospital
Schizophrenia, Schizoaffective Disorder
Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia
The main aim of the trial is to study whether a change of medication in non-responders to a two-weeks antipsychotic drug trial is more effective than continued treatment with the same antipsychotic.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT01029769
- Testing
- Olanzapine or amisulpride
- Where
- Germany
- Volunteers
- 350 people
- Sponsor
- Technical University of Munich
Schizophrenia, Schizoaffective Disorder
Cognitive-Behavioral Therapy in Veterans With Schizophrenia
This is a study comparing the benefits of two types of individual psychotherapy (cognitive-behavioral therapy for psychosis and supportive therapy) in symptomatic Veteran outpatients diagnosed with schizophrenia or…
- Trial name
- NCT00688259
- Testing
- Supportive Therapy (ST), Cognitive Behavioral Therapy for Psychosis (CBTp)
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- VA Office of Research and Development
Psychosis
Effectiveness of Cognitive Remediation in a Supported Education Setting
The purpose of this study is to determine whether cognitive remediation as an adjunct to supported education, will result in improved cognitive functioning, symptoms, and performance in academic domains for persons with psychosis…
- Trial name
- NCT01492439
- Testing
- Cognitive Remediation, Supported Education
- Where
- 2 sites in Canada
- Volunteers
- 37 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy
Evaluate the safety and tolerability of multiple subcutaneous injections of various dosages of risperidone with clinically stable schizophrenia
- Trial name
- NCT01677377
- Testing
- Risperidone, RBP-7000
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Indivior Inc.
Schizophrenia, Schizo Affective Disorder
Models of Auditory Hallucination
The purpose of this study is to address the shortcoming in clinical hallucination research by causally manipulating the neural loci of conditioned hallucination task behavior in-person in patients with psychosis using…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Auditory Hallucination
- Trial name
- NCT04210557
- Testing
- Transcranial Magnetic Stimulation (TMS)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Yale University
Schizophrenia, Alcohol Use Disorder
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
This double-blind, randomized study will evaluate the efficacy, safety and tolerability of ALKS 3831 in subjects with schizophrenia and alcohol use disorder (AUD).
- Trial name
- NCT02161718
- Testing
- Samidorphan + olanzapine (ALKS 3831)
- Where
- 71 sites in United States, Bulgaria and 1 more
- Volunteers
- 300 people
- Sponsor
- Alkermes, Inc.
Schizophrenia, Schizoaffective Disorder
Stimulating the Brain to Improve Self-Awareness
This study investigates whether Introspective Accuracy (IA) can be improved in individuals with schizophrenia by stimulating the brain via transcranial Direct Current Stimulation (tDCS).
- Trial name
- NCT03370341
- Testing
- active anodal tDCS
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- The University of Texas at Dallas
Schizophrenia
Improving Cognition in Schizophrenia Using tDCS
This study will examine the benefits of transcranial direct current stimulation (tDCS), a new tool that is being developed as a safe and non-invasive neurostimulation method, for improving neurocognitive and social cognitive…
- Trial name
- ICDC (NCT02539797)
- Testing
- tDCS
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of California, Los Angeles
Schizophrenia, Schizoaffective Disorder
Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone
The primary objective of this study is to evaluate change in weight as a result of switching from quetiapine to ziprasidone, in subjects with schizophrenia or schizoaffective disorder who have failed to achieve a satisfactory…
- Trial name
- NCT00406315
- Testing
- ziprasidone
- Where
- 40 sites in United States, Brazil and 4 more
- Volunteers
- 255 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.